Can low thyroid hormone availability, mineral insufficiency, and impaired lipid clearance compound cardiovascular risk?

Low thyroid hormone availability has a well-established role in reducing intracellular T3-dependent signaling and in impairing hepatic pathways relevant to LDL clearance. The proposed broader interaction with mineral status is biologically credible but remains clinically unproven.

Clinical and cardiovascular evidence

• Cardiovascular risk is most clearly associated with more substantial subclinical hypothyroidism. In an individual-participant meta-analysis of 55,287 people, TSH 10–19.9 mIU/L was associated with higher coronary heart-disease events (HR 1.89, 95% CI 1.28–2.80) and coronary mortality (HR 1.58, 95% CI 1.10–2.27).
• Heart-failure risk similarly rose chiefly at TSH ≥10 mIU/L (HR 1.86, 95% CI 1.27–2.72). In contrast, TSH 4.5–6.9 mIU/L was not associated with excess coronary events.
• For milder subclinical abnormalities, consistent LDL-C reduction, cardiovascular-event prevention, or benefit from routine levothyroxine has not been demonstrated; management is therefore individualized for TSH 4–10 mIU/L.

Mechanistic context

• Intracellular T3 regulates target genes through thyroid-hormone receptors. In the liver, T3/TRβ signaling promotes LDL-receptor transcription, including through SREBP-2, increasing LDL uptake. It also supports cholesterol elimination through CYP7A1-mediated bile-acid synthesis.
• Zinc plausibly influences thyroid-hormone synthesis, action, and deiodinase-mediated local T3 availability, creating a potential indirect route to altered lipid clearance. Evidence for magnesium in this pathway is not established.
• Zinc supplementation has produced a modest average LDL-C reduction of approximately 7 mg/dL in controlled trials, but this does not demonstrate improved LDL-receptor clearance or ApoB reduction.

Bottom line

• Suboptimal thyroid signaling is an established cardiovascular risk modifier chiefly when dysfunction is substantial and persistent (particularly TSH ≥10 mIU/L). Thyroid-dependent impairment of LDL clearance is mechanistically well supported; zinc-related interaction is plausible, whereas combined clinical effects—and magnesium-specific effects—remain unproven.